Gregory Renza
Stock Analyst at RBC Capital
(2.07)
# 2,878
Out of 4,749 analysts
216
Total ratings
35.16%
Success rate
-4.64%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $26 → $27 | $19.71 | +36.99% | 11 | Jan 29, 2025 | |
| AMGN Amgen | Reiterates: Outperform | $324 | $285.42 | +13.52% | 16 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $61 | $24.35 | +150.51% | 12 | Jan 15, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $16 | $3.55 | +350.70% | 5 | Jan 14, 2025 | |
| PCRX Pacira BioSciences | Reiterates: Sector Perform | $18 | $26.33 | -31.64% | 11 | Jan 14, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $68 → $48 | $6.06 | +692.08% | 4 | Jan 9, 2025 | |
| VSTM Verastem | Maintains: Outperform | $13 → $16 | $6.08 | +163.16% | 9 | Jan 7, 2025 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $6 → $10 | $2.31 | +332.90% | 6 | Jan 7, 2025 | |
| CRMD CorMedix | Maintains: Outperform | $11 → $12 | $10.27 | +16.85% | 5 | Dec 19, 2024 | |
| MNKD MannKind | Upgrades: Outperform | $7 → $10 | $5.79 | +72.71% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $19.38 | +142.52% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $18.58 | +83.04% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $179 | $124.37 | +43.93% | 12 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 → $1.5 | $0.38 | +300.00% | 13 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $34.39 | +65.75% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $66 | $30.07 | +119.49% | 2 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $6 | $2.09 | +187.08% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $2 | $0.15 | +1,220.13% | 8 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $3.96 | +1.01% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $11 → $2 | $0.65 | +208.83% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $35 | $13.39 | +161.39% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $34 | $33.15 | +2.56% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $18.28 | +86.00% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.86 | +314.51% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $26 | $18.66 | +39.34% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.68 | +376.19% | 11 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $18 | $0.18 | +10,127.27% | 7 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $8.42 | +2,037.77% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $3.91 | +1,946.04% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $1.60 | +1,775.00% | 3 | Jun 2, 2020 |
Nurix Therapeutics
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $19.71
Upside: +36.99%
Amgen
Jan 24, 2025
Reiterates: Outperform
Price Target: $324
Current: $285.42
Upside: +13.52%
IDEAYA Biosciences
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $24.35
Upside: +150.51%
Perspective Therapeutics
Jan 14, 2025
Reiterates: Outperform
Price Target: $16
Current: $3.55
Upside: +350.70%
Pacira BioSciences
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $26.33
Upside: -31.64%
Jasper Therapeutics
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $6.06
Upside: +692.08%
Verastem
Jan 7, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $6.08
Upside: +163.16%
Nuvation Bio
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $2.31
Upside: +332.90%
CorMedix
Dec 19, 2024
Maintains: Outperform
Price Target: $11 → $12
Current: $10.27
Upside: +16.85%
MannKind
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $5.79
Upside: +72.71%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $19.38
Upside: +142.52%
Dec 13, 2024
Initiates: Outperform
Price Target: $34
Current: $18.58
Upside: +83.04%
Dec 12, 2024
Reiterates: Outperform
Price Target: $179
Current: $124.37
Upside: +43.93%
Dec 11, 2024
Reiterates: Sector Perform
Price Target: $2 → $1.5
Current: $0.38
Upside: +300.00%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $34.39
Upside: +65.75%
Dec 6, 2024
Reiterates: Outperform
Price Target: $66
Current: $30.07
Upside: +119.49%
Nov 15, 2024
Maintains: Sector Perform
Price Target: $7 → $6
Current: $2.09
Upside: +187.08%
Nov 14, 2024
Maintains: Outperform
Price Target: $4 → $2
Current: $0.15
Upside: +1,220.13%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $3.96
Upside: +1.01%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $0.65
Upside: +208.83%
Nov 1, 2024
Reiterates: Outperform
Price Target: $35
Current: $13.39
Upside: +161.39%
Oct 30, 2024
Reiterates: Outperform
Price Target: $34
Current: $33.15
Upside: +2.56%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $18.28
Upside: +86.00%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.86
Upside: +314.51%
Aug 7, 2024
Maintains: Outperform
Price Target: $29 → $26
Current: $18.66
Upside: +39.34%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.68
Upside: +376.19%
Nov 10, 2023
Maintains: Outperform
Price Target: $23 → $18
Current: $0.18
Upside: +10,127.27%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $8.42
Upside: +2,037.77%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $3.91
Upside: +1,946.04%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $1.60
Upside: +1,775.00%